Pharmas patent cliff isnt just about expiration dates. Its about how those dates are engineered.
For years, the industry has treated method-of-use patents like a footnotesomething technical, something legal, something that happens in the background whi…

The Patent Dance Is Not a DanceIts a Deadline. Heres How Biosimilar Developers Actually Win (or Lose) Before Court Ever Opens.
If youve ever watched the patent dance play out in biosimilars, you might think its mostly legal theater: notices, exchanges,…

Most teams dont lose to competitorsthey lose to time.
In pharma, time isnt just a calendar problem. Its a patent problem. And if youre still waiting for legal notices, office actions, or late-stage signals to understand when exclusivity might endand …

Patent thickets arent just a legal inconveniencetheyre a market design problem. When a single products IP landscape becomes a maze of overlapping Orange Book listings, method-of-use claims, formulation patents, and ever-shifting litigation timelines, t…

Blockbuster patents dont just protect moleculesthey protect how the molecule is made.
Thats the uncomfortable truth behind formulation forensics: the idea that if you want to design around a blockbuster drug patent, you cant stop at the active ingred…

Pharma boards dont fear litigation. They fear what litigation does to decisions.
When a patent case lands on the deskespecially one involving a blockbuster or a platform assetthe immediate question is usually legal: Who wins? But the board-level questi…

Generic drug developers dont lose to bad luck. They lose to design choices made too late.
If youre building a generic pipeline, formulation patents can feel like an ambush: you think youre competing on bioequivalence and manufacturing efficiencythen …

Pharma Forensics: The Quiet Skill That Lets You Decode a Competitors Lifecycle Strategy
In pharma, the loudest signals are rarely the most important.
A press release about pipeline momentum can be trueand still miss the real story. The real story is of…

Designing Around the Moat: How Generic Developers Can Win the Secondary-Patent Game
In generic drug development, the first patent is rarely the whole story.
Yes, the primary patent often grabs headlinesexpiration dates, Paragraph IV challenges, and the…

Patent cliffs arent just a legal eventtheyre a supply-chain stress test.
If youre responsible for procurement, planning, manufacturing, or commercial operations, the next wave of blockbuster expirations will hit like weather: predictable in theory, d…